Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.

Katewa A, Wang Y, Hackney JA, Huang T, Suto E, Ramamoorthi N, Austin CD, Bremer M, Chen JZ, Crawford JJ, Currie KS, Blomgren P, DeVoss J, DiPaolo JA, Hau J, Johnson A, Lesch J, DeForge LE, Lin Z, Liimatta M, Lubach JW, McVay S, Modrusan Z, Nguyen A, Poon C, Wang J, Liu L, Lee WP, Wong H, Young WB, Townsend MJ, Reif K.

JCI Insight. 2017 Apr 6;2(7):e90111. doi: 10.1172/jci.insight.90111.

2.

Characterization of a sensitive mouse Aβ40 PD biomarker assay for Alzheimer's disease drug development in wild-type mice.

Lu Y, Hoyte K, Montgomery WH, Luk W, He D, Meilandt WJ, Zuchero YJ, Atwal JK, Scearce-Levie K, Watts RJ, DeForge LE.

Bioanalysis. 2016 May;8(10):1067-75. doi: 10.4155/bio-2016-0003. Epub 2016 Apr 20.

PMID:
27094761
3.

A novel immunoassay to measure total serum lymphotoxin-α levels in the presence of an anti-LTα therapeutic antibody.

Young J, Nguyen A, Qiu ZJ, Ying Y, Gao X, Reed C, Chuntharapai A, Deng R, Lutman J, Grogan J, Wong WL, DeForge L.

J Immunol Methods. 2015 Sep;424:91-9. doi: 10.1016/j.jim.2015.05.006. Epub 2015 May 23.

PMID:
26009247
4.

Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus.

Lin W, Seshasayee D, Lee WP, Caplazi P, McVay S, Suto E, Nguyen A, Lin Z, Sun Y, DeForge L, Balazs M, Martin F, Zarrin AA.

Arthritis Rheumatol. 2015 Jan;67(1):215-24. doi: 10.1002/art.38907.

5.

Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration.

Loyet KM, Good J, Davancaze T, Sturgeon L, Wang X, Yang J, Le KN, Wong M, Hass PE, van Lookeren Campagne M, Haughney PC, Morimoto A, Damico-Beyer LA, DeForge LE.

J Pharmacol Exp Ther. 2014 Dec;351(3):527-37. doi: 10.1124/jpet.114.215921. Epub 2014 Sep 17.

PMID:
25232192
6.

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys.

Leabman MK, Meng YG, Kelley RF, DeForge LE, Cowan KJ, Iyer S.

MAbs. 2013 Nov-Dec;5(6):896-903. doi: 10.4161/mabs.26436.

7.

Polyclonal hyper-IgE mouse model reveals mechanistic insights into antibody class switch recombination.

Misaghi S, Senger K, Sai T, Qu Y, Sun Y, Hamidzadeh K, Nguyen A, Jin Z, Zhou M, Yan D, Lin WY, Lin Z, Lorenzo MN, Sebrell A, Ding J, Xu M, Caplazi P, Austin CD, Balazs M, Roose-Girma M, DeForge L, Warming S, Lee WP, Dixit VM, Zarrin AA.

Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15770-5. doi: 10.1073/pnas.1221661110. Epub 2013 Sep 9.

8.

Micro-volume wall-less immunoassays using patterned planar plates.

Kozak KR, Wang J, Lye M, Chuh Jd, Takkar R, Kim N, Lee H, Jeon NL, Lin K, Zhang C, Wong WL, DeForge LE.

Lab Chip. 2013 Apr 7;13(7):1342-50. doi: 10.1039/c3lc40973b.

PMID:
23380873
9.

Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration.

Loyet KM, Deforge LE, Katschke KJ Jr, Diehl L, Graham RR, Pao L, Sturgeon L, Lewin-Koh SC, Hollyfield JG, van Lookeren Campagne M.

Invest Ophthalmol Vis Sci. 2012 Sep 25;53(10):6628-37.

PMID:
22930722
10.

A case study on Sema3E-Fc aggregation and assay-dependent differences in quantitation.

Bumbaca D, Tong RK, Koch AW, Xiang H, DeForge LE, Shen BQ, Lu Y.

Bioanalysis. 2012 Mar;4(6):703-11. doi: 10.4155/bio.12.30.

PMID:
22452261
11.

Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice.

Deng R, Meng YG, Hoyte K, Lutman J, Lu Y, Iyer S, DeForge LE, Theil FP, Fielder PJ, Prabhu S.

MAbs. 2012 Jan-Feb;4(1):101-9. doi: 10.4161/mabs.4.1.18543.

12.

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, Carano RA, Darrow J, Davies DR, DeForge LE, Diehl L, Ferrando R, Gallion SL, Giannetti AM, Gribling P, Hurez V, Hymowitz SG, Jones R, Kropf JE, Lee WP, Maciejewski PM, Mitchell SA, Rong H, Staker BL, Whitney JA, Yeh S, Young WB, Yu C, Zhang J, Reif K, Currie KS.

Nat Chem Biol. 2011 Jan;7(1):41-50. doi: 10.1038/nchembio.481. Epub 2010 Nov 28.

PMID:
21113169
13.

Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF.

DeForge LE, Loyet KM, Delarosa D, Chinn J, Zamanian F, Chuntharapai A, Lee J, Hass P, Wei N, Townsend MJ, Wang J, Wong WL.

J Immunol Methods. 2010 Oct 31;362(1-2):70-81. doi: 10.1016/j.jim.2010.09.004. Epub 2010 Sep 9.

PMID:
20833179
14.

Increased targeting of donor switch region and IgE in Sgamma1-deficient B cells.

Misaghi S, Garris CS, Sun Y, Nguyen A, Zhang J, Sebrell A, Senger K, Yan D, Lorenzo MN, Heldens S, Lee WP, Xu M, Wu J, DeForge L, Sai T, Dixit VM, Zarrin AA.

J Immunol. 2010 Jul 1;185(1):166-73. doi: 10.4049/jimmunol.1000515. Epub 2010 May 28.

15.

Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice.

Brightbill HD, Jeet S, Lin Z, Yan D, Zhou M, Tan M, Nguyen A, Yeh S, Delarosa D, Leong SR, Wong T, Chen Y, Ultsch M, Luis E, Ramani SR, Jackman J, Gonzalez L, Dennis MS, Chuntharapai A, DeForge L, Meng YG, Xu M, Eigenbrot C, Lee WP, Refino CJ, Balazs M, Wu LC.

J Clin Invest. 2010 Jun;120(6):2218-29. doi: 10.1172/JCI40141. Epub 2010 May 10.

16.

Lymphotoxin-alphabeta heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis.

Young J, Yu X, Wolslegel K, Nguyen A, Kung C, Chiang E, Kolumam G, Wei N, Wong WL, DeForge L, Townsend MJ, Grogan JL.

Cytokine. 2010 Jul;51(1):78-86. doi: 10.1016/j.cyto.2010.03.003. Epub 2010 Mar 31.

PMID:
20356761
17.

Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.

Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, Prabhu S.

Drug Metab Dispos. 2010 Apr;38(4):600-5. doi: 10.1124/dmd.109.031310. Epub 2010 Jan 13.

PMID:
20071453
18.

Improving therapeutic efficacy of a complement receptor by structure-based affinity maturation.

Li B, Xi H, Diehl L, Lee WP, Sturgeon L, Chinn J, Deforge L, Kelley RF, Wiesmann C, van Lookeren Campagne M, Sidhu SS.

J Biol Chem. 2009 Dec 18;284(51):35605-11. doi: 10.1074/jbc.M109.035170.

19.

Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study.

Loyet KM, Deng R, Liang WC, Wu Y, Lowman HB, DeForge LE.

J Immunol Methods. 2009 Jun 30;345(1-2):17-28. doi: 10.1016/j.jim.2009.03.012. Epub 2009 Apr 2.

PMID:
19345224
20.

Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement.

Katschke KJ Jr, Stawicki S, Yin J, Steffek M, Xi H, Sturgeon L, Hass PE, Loyet KM, Deforge L, Wu Y, van Lookeren Campagne M, Wiesmann C.

J Biol Chem. 2009 Apr 17;284(16):10473-9. doi: 10.1074/jbc.M809106200. Epub 2009 Feb 5.

21.

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.

Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A.

Cell Death Differ. 2008 Apr;15(4):751-61. doi: 10.1038/sj.cdd.4402306. Epub 2008 Jan 25.

22.

Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade.

Lin WY, Gong Q, Seshasayee D, Lin Z, Ou Q, Ye S, Suto E, Shu J, Lee WP, Lee CW, Fuh G, Leabman M, Iyer S, Howell K, Gelzleichter T, Beyer J, Danilenko D, Yeh S, DeForge LE, Ebens A, Thompson JS, Ambrose C, Balazs M, Starovasnik MA, Martin F.

Blood. 2007 Dec 1;110(12):3959-67. Epub 2007 Aug 8.

PMID:
17687108
23.

Species-dependent serum interference in a sandwich ELISA for Apo2L/TRAIL.

DeForge LE, Shih DH, Kennedy D, Totpal K, Chuntharapai A, Bennett GL, Drummond JH, Siguenza P, Wong WL.

J Immunol Methods. 2007 Mar 30;320(1-2):58-69. Epub 2007 Jan 5.

PMID:
17280683
24.

Structure of C3b in complex with CRIg gives insights into regulation of complement activation.

Wiesmann C, Katschke KJ, Yin J, Helmy KY, Steffek M, Fairbrother WJ, McCallum SA, Embuscado L, DeForge L, Hass PE, van Lookeren Campagne M.

Nature. 2006 Nov 9;444(7116):217-20. Epub 2006 Oct 15.

PMID:
17051150
25.

Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells.

Lee CV, Hymowitz SG, Wallweber HJ, Gordon NC, Billeci KL, Tsai SP, Compaan DM, Yin J, Gong Q, Kelley RF, DeForge LE, Martin F, Starovasnik MA, Fuh G.

Blood. 2006 Nov 1;108(9):3103-11. Epub 2006 Jul 13.

PMID:
16840730
26.

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.

Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A.

J Biol Chem. 2005 Jan 21;280(3):2205-12. Epub 2004 Nov 1.

27.

Substrate capacity considerations in developing kinase assays.

DeForge LE, Cochran AG, Yeh SH, Robinson BS, Billeci KL, Wong WL.

Assay Drug Dev Technol. 2004 Apr;2(2):131-40.

PMID:
15165509
28.

Design, construction, and in vitro analyses of multivalent antibodies.

Miller K, Meng G, Liu J, Hurst A, Hsei V, Wong WL, Ekert R, Lawrence D, Sherwood S, DeForge L, Gaudreault J, Keller G, Sliwkowski M, Ashkenazi A, Presta L.

J Immunol. 2003 May 1;170(9):4854-61.

29.

Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.

Leong SR, DeForge L, Presta L, Gonzalez T, Fan A, Reichert M, Chuntharapai A, Kim KJ, Tumas DB, Lee WP, Gribling P, Snedecor B, Chen H, Hsei V, Schoenhoff M, Hale V, Deveney J, Koumenis I, Shahrokh Z, McKay P, Galan W, Wagner B, Narindray D, Hébert C, Zapata G.

Cytokine. 2001 Nov 7;16(3):106-19.

PMID:
11741351
30.
31.

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.

Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A.

Nat Med. 2001 Apr;7(4):383-5. No abstract available.

PMID:
11283636
32.

A neutralizing monoclonal antibody specific for the dimer interface region of IL-8.

Deforge LE, Lowman HB, Leong SR, Chuntharapai A, Jin Kim K, Hébert CA.

Cytokine. 2000 Nov;12(11):1620-9.

PMID:
11052812
34.

Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific PEGylation with preserved bioactivity.

Koumenis IL, Shahrokh Z, Leong S, Hsei V, Deforge L, Zapata G.

Int J Pharm. 2000 Mar 30;198(1):83-95.

PMID:
10722953
35.

Safety and antitumor activity of recombinant soluble Apo2 ligand.

Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH.

J Clin Invest. 1999 Jul;104(2):155-62.

36.

IL-8 single-chain homodimers and heterodimers: interactions with chemokine receptors CXCR1, CXCR2, and DARC.

Leong SR, Lowman HB, Liu J, Shire S, Deforge LE, Gillece-Castro BL, McDowell R, Hébert CA.

Protein Sci. 1997 Mar;6(3):609-17.

37.

Biological assays for C-X-C chemokines.

Baly D, Gibson U, Allison D, DeForge L.

Methods Enzymol. 1997;287:69-88. No abstract available.

PMID:
9330316
38.

Exchanging interleukin-8 and melanoma growth-stimulating activity receptor binding specificities.

Lowman HB, Slagle PH, DeForge LE, Wirth CM, Gillece-Castro BL, Bourell JH, Fairbrother WJ.

J Biol Chem. 1996 Jun 14;271(24):14344-52.

39.

Is Still's disease associated with parvovirus B19 infection?

Godeau B, Palazzo E, Morinet F, Deplanche M, Deforge L, Schaeffer A, Kahn MF.

Lancet. 1995 Jan 7;345(8941):59-60. No abstract available.

PMID:
7799719
41.

Interleukin 8 in serum in granulocytopenic patients with infections.

Waage A, Remick D, Steinshamn S, Deforge L, Lamvik J.

Br J Haematol. 1994 Jan;86(1):36-40.

PMID:
8011545
42.

Regulation of interleukin 8 gene expression by oxidant stress.

DeForge LE, Preston AM, Takeuchi E, Kenney J, Boxer LA, Remick DG.

J Biol Chem. 1993 Dec 5;268(34):25568-76.

43.

Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture.

Wollenberg GK, DeForge LE, Bolgos G, Remick DG.

Am J Pathol. 1993 Oct;143(4):1121-30.

44.

Oxygen radical scavengers selectively inhibit interleukin 8 production in human whole blood.

DeForge LE, Fantone JC, Kenney JS, Remick DG.

J Clin Invest. 1992 Nov;90(5):2123-9.

45.

Comparison of methods for incorporating a radioiodinated residualizing cholesteryl ester analog into low density lipoprotein.

Deforge LE, Degalan MR, Ruyan MK, Newton RS, Counsell RE.

Int J Rad Appl Instrum B. 1992 Oct;19(7):775-82.

46.

Local production of interleukin-8 is associated with nosocomial pneumonia.

Rodriguez JL, Miller CG, DeForge LE, Kelty L, Shanley CJ, Bartlett RH, Remick DG.

J Trauma. 1992 Jul;33(1):74-81; discussion 81-2.

PMID:
1635109
47.
48.

Detection of plasma tumor necrosis factor, interleukins 6, and 8 during the Jarisch-Herxheimer Reaction of relapsing fever.

Negussie Y, Remick DG, DeForge LE, Kunkel SL, Eynon A, Griffin GE.

J Exp Med. 1992 May 1;175(5):1207-12.

49.
50.

Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.

Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, DeForge L, Kenney JS, Remick DG, Bloedow DC, et al.

J Clin Invest. 1992 May;89(5):1551-7.

Supplemental Content

Loading ...
Support Center